| P50 | author | Thomas Efferth | Q53683811 |
| P2093 | author name string | Joachim Arend | |
| | Benjamin Krusche | |
| P2860 | cites work | Experimental Therapy of Hepatoma with Artemisinin and Its Derivatives: In vitro and In vivo Activity, Chemosensitization, and Mechanisms of Action | Q22061792 |
| | Artemisinins target the SERCA of Plasmodium falciparum | Q22061877 |
| | Angiogenesis in cancer and other diseases | Q27861015 |
| | Combination antiangiogenesis therapy with marimastat, captopril and fragmin in patients with advanced cancer | Q28168748 |
| | Development of resistance towards artesunate in MDA-MB-231 human breast cancer cells | Q28478307 |
| | Molecular Target-Guided Tumor Therapy with Natural Products Derived from Traditional Chinese Medicine | Q29031416 |
| | Mind-body therapies in integrative oncology. | Q30396805 |
| | Integrative oncology: managing cancer pain with complementary and alternative therapies | Q30417297 |
| | Theoretical rationale for music selection in oncology intervention research: an integrative review | Q30419249 |
| | Artesunate induces oncosis-like cell death in vitro and has antitumor activity against pancreatic cancer xenografts in vivo | Q33666019 |
| | Inhibition of tumor angiogenesis by antibodies, synthetic small molecules and natural products. | Q33932025 |
| | Cytotoxicity of artemisinin-related endoperoxides to Ehrlich ascites tumor cells. | Q50782379 |
| | First study of oral Artenimol-R in advanced cervical cancer: clinical benefit, tolerability and tumor markers. | Q54540620 |
| | Chemoprevention of breast cancer | Q57133081 |
| | Detection of apoptosis in KG-1a leukemic cells treated with investigational drugs | Q71292134 |
| | In vitro and in vivo induction of antiangiogenic activity by plasminogen activators and captopril | Q73082176 |
| | Captopril augments antitumor activity of cyclophosphamide in mice | Q73252129 |
| | Inhibition of angiogenesis in Kaposi's sarcoma by captopril | Q73253004 |
| | [Understanding the organism as a central problem medicine] | Q74389173 |
| | Anthracycline-derived chemotherapeutics in apoptosis and free radical cytotoxicity (Review) | Q77678739 |
| | Inhibition of gelatinase A (MMP-2) by batimastat and captopril reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma | Q77751600 |
| | Studies on the constituents of Artemisia annua Part II | Q80081387 |
| | Artesunate attenuates the growth of human colorectal carcinoma and inhibits hyperactive Wnt/beta-catenin pathway | Q80372653 |
| | Anti-tumor activity of a combination of plasminogen activator and captopril in a human melanoma xenograft model | Q80535044 |
| | Qinghaosu (artemisinin): an antimalarial drug from China | Q34193570 |
| | The history of qing hao in the Chinese materia medica | Q34505889 |
| | Captopril as a potential inhibitor of lung tumor growth and metastasis | Q34846520 |
| | Artemisinin: mechanisms of action, resistance and toxicity | Q34999485 |
| | Future directions of CAM research in pediatric oncology | Q36562552 |
| | Application of an image analysis system to the quantitation of tumor perfusion and vascularity in human glioma xenografts | Q36788515 |
| | Principles to guide integrative oncology and the development of an evidence base | Q36860311 |
| | From traditional Chinese medicine to rational cancer therapy. | Q36888420 |
| | Dietary phytochemicals and cancer prevention: Nrf2 signaling, epigenetics, and cell death mechanisms in blocking cancer initiation and progression. | Q36961488 |
| | Management of hypertension in patients with cardiac disease: use of renin-angiotensin blocking agents | Q37220676 |
| | Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats | Q37358195 |
| | Toxicity of the antimalarial artemisinin and its dervatives. | Q37693152 |
| | Personalized cancer medicine: from molecular diagnostics to targeted therapy with natural products. | Q37756695 |
| | Stem cells, cancer stem-like cells, and natural products. | Q38008969 |
| | Target-oriented mechanisms of novel herbal therapeutics in the chemotherapy of gastrointestinal cancer and inflammation | Q38040833 |
| | Mechanisms of resistance to anti-angiogenesis therapies | Q38090874 |
| | Anti-inflammatory phytochemicals for chemoprevention of colon cancer. | Q38099875 |
| | Effects of artesunate on cytokinesis and G₂/M cell cycle progression of tumour cells and budding yeast. | Q38338694 |
| | Adverse reactions with angiotensin converting enzyme (ACE) inhibitors | Q39505837 |
| | Artesunate derived from traditional Chinese medicine induces DNA damage and repair. | Q39976238 |
| | Microarray expression profiles of angiogenesis-related genes predict tumor cell response to artemisinins. | Q40325894 |
| | Artesunate in the treatment of metastatic uveal melanoma--first experiences | Q40374633 |
| | Effects of the angiotensin-I converting enzyme inhibitor perindopril on tumor growth and angiogenesis in head and neck squamous cell carcinoma cells. | Q40510842 |
| | Artesunate reduces chicken chorioallantoic membrane neovascularisation and exhibits antiangiogenic and apoptotic activity on human microvascular dermal endothelial cell | Q40541235 |
| | Inhibitory effects of artesunate on angiogenesis and on expressions of vascular endothelial growth factor and VEGF receptor KDR/flk-1. | Q40571989 |
| | Captopril inhibits tumour growth in a xenograft model of human renal cell carcinoma | Q41053553 |
| | Sequential development of angiotensin receptors and angiotensin I converting enzyme during angiogenesis in the rat subcutaneous sponge granuloma. | Q41973411 |
| | Association of ACE inhibitors and angiotensin receptor blockers with keratinocyte cancer prevention in the randomized VATTC trial | Q42440771 |
| | The angiotensin-I-converting enzyme inhibitor enalapril and aspirin delay progression of pancreatic intraepithelial neoplasia and cancer formation in a genetically engineered mouse model of pancreatic cancer | Q43251051 |
| | The anti-malarial artesunate is also active against cancer | Q43543737 |
| | Angiotensin II and VEGF are involved in angiogenesis induced by short-term exercise training | Q43713888 |
| | Antiviral activity of artesunate towards wild-type, recombinant, and ganciclovir-resistant human cytomegaloviruses. | Q43971464 |
| | Inhibition of human cancer cell line growth and human umbilical vein endothelial cell angiogenesis by artemisinin derivatives in vitro | Q44512939 |
| | Antimalarial dihydroartemisinin also inhibits angiogenesis | Q44887293 |
| | Inhibition of angiogenesis in vivo and growth of Kaposi's sarcoma xenograft tumors by the anti-malarial artesunate | Q45153374 |
| | Oral administration of dihydroartemisinin and ferrous sulfate retarded implanted fibrosarcoma growth in the rat. | Q47637894 |
| | Captopril ameliorates myocardial and hematological toxicities induced by adriamycin | Q47790508 |
| | Artesunate induces oxidative DNA damage, sustained DNA double-strand breaks, and the ATM/ATR damage response in cancer cells | Q47992452 |
| P275 | copyright license | Creative Commons Attribution 3.0 Unported | Q14947546 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | artesunate | Q707939 |
| P304 | page(s) | 454783 | |
| P577 | publication date | 2013-10-08 | |
| P1433 | published in | Evidence-based Complementary and Alternative Medicine | Q5418319 |
| P1476 | title | Synergistic inhibition of angiogenesis by artesunate and captopril in vitro and in vivo. | |
| P478 | volume | 2013 | |